PRECISION BIOSCIENCES INC 8-K

What Happened
On March 12, 2026, Precision BioSciences, Inc. (DTIL) announced and furnished a press release reporting its financial results for the quarter and year ended December 31, 2025. The press release is provided as Exhibit 99.1 to the Form 8-K and is incorporated by reference; the report was signed by Chief Financial Officer John Alexander Kelly.

Key Details

• Filing date: March 12, 2026.
• Reporting period: quarter and year ended December 31, 2025.
• Press release furnished as Exhibit 99.1 (text of earnings announcement).
• Form 8-K was signed by John Alexander Kelly, Chief Financial Officer.

Why It Matters
This 8-K signals that Precision BioSciences has publicly released its quarterly and full-year 2025 results — investors should review the Exhibit 99.1 press release for concrete figures (revenue, earnings/loss, cash position, and any guidance or operational updates). The Form 8-K itself furnishes the announcement; detailed audited financial statements and additional disclosures may follow in the company’s periodic filings (10-K/10-Q).